OmniAb, Inc. Stock Price, News & Analysis

OmniAb (NASDAQ: OABI) reported third quarter 2025 results on November 4, 2025: Q3 revenue $2.2M versus $4.2M year-ago and Q3 net loss $16.5M ($0.14/share). Nine-month revenue was $10.3M and nine-month net loss was $50.6M ($0.46/share).

The company ended September 30, 2025 with $59.5M in cash and equivalents after an August private placement that raised $30M (~$28M net). 2025 guidance: revenue $18–22M, operating expense $82–86M, year-end cash expected $52–56M. OmniAb reported 104 active partners, 399 active programs and 32 programs in clinical development or commercialization; OmniUltra™ launch planned for December 2025.

OmniAb (NASDAQ: OABI) announced management participation in three investor conferences in November 2025. Key events:

• Truist Securities BioPharma Symposium — November 6, Lotte New York Palace Hotel; Matt Foehr, CEO, will hold one-on-one investor meetings.
• Stifel Healthcare Conference — November 11-13, Lotte New York Palace Hotel; Kurt Gustafson, CFO, will hold one-on-one investor meetings on November 12.
• Jefferies Global Healthcare Conference — London — November 17-20, Waldorf Hilton; Matt Foehr will present a corporate overview on November 19 at 8:00 a.m. GMT and hold meetings on November 18-19.

The schedule highlights management access to investors via presentations and one-on-one meetings across U.S. and London industry conferences.

OmniAb (NASDAQ: OABI) will report third quarter 2025 financial results for the three and nine months ended September 30, 2025 after U.S. market close on Tuesday, November 4, 2025. The company will host a conference call and webcast the same day beginning at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and business updates.

Participants can join by phone (U.S. dial-in (800) 549 8228; international (646) 564 8277; Conference ID 92631). A live webcast and replay with slides will be available via the company’s webcast link.

OmniAb (NASDAQ: OABI) announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025, at the Lotte New York Palace Hotel. The company's management team will be available for one-on-one meetings with registered investors on September 9, 2025.

Interested investors can schedule meetings through their H.C. Wainwright representative or by emailing meetings@hcwco.com.

OmniAb (NASDAQ: OABI) has announced a private placement to raise approximately $30 million through the sale of 21,254,106 shares of common stock. The shares will be priced at $1.40 per share, with officer and director participants paying $1.85 per share.

The placement, expected to close around August 26, 2025, includes participation from top-tier new and existing investors, along with company officers and directors. Leerink Partners is serving as the sole placement agent. The proceeds will be used for general corporate purposes, and OmniAb will file a registration statement with the SEC for the resale of these shares.

OmniAb (NASDAQ: OABI) reported Q2 2025 financial results, showing revenue of $3.9 million, down from $7.6 million in Q2 2024. The company posted a net loss of $15.9 million ($0.15 per share). Despite lower revenue, OmniAb achieved significant business milestones, reaching 100 active partners and 381 active programs, including 32 OmniAb-derived programs in clinical development or commercialization.

The company launched the xPloration® Partner Access Program and entered six new license agreements. Notable highlights include partner Immunovant initiating Phase 3 trials for IMVT-1402, and Johnson & Johnson's JNJ-5322 showing 100% overall response rate in initial Phase 1 results. OmniAb maintains its 2025 revenue guidance of $20-25 million and expects operating expenses of $85-90 million.

OmniAb (NASDAQ: OABI) has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern time to discuss the results and provide business updates.

Interested parties can access the call via phone using U.S. number (800) 549 8228 or international number (289) 819 1520 with Conference ID 93102. A live webcast with slides will also be available for viewing.

OmniAb (NASDAQ: OABI) showcased its innovative xPloration platform at the 21st Annual PEGS Boston Summit. The platform is a high-throughput single B-cell screening technology that leverages machine learning and AI for antibody discovery. xPloration processes millions of single B-cells and identifies thousands of antibody variants within hours, screening 10 times more single cells per day than other spatial separation techniques.

Key features include a laser-based "touchless" cell recovery process, short 1.5-hour instrument run times, and AI-assisted image analysis. The platform supports various assay formats, including multiplex cell surface binding and cross-blocking assays. OmniAb has launched a Partner Access Program, allowing current partners to purchase the instrument for their laboratories.

OmniAb (NASDAQ: OABI) reported Q1 2025 financial results with revenue of $4.2 million, up from $3.8 million in Q1 2024. The company posted a net loss of $18.2 million ($0.17 per share), compared to $19.0 million loss in Q1 2024. Key highlights include: three new platform license agreements, 95 active partners, and 378 active programs. The company affirmed 2025 revenue guidance of $20-25 million and revised operating expenses to $85-90 million. Notable developments include a $3 million upfront payment from Angelini Pharma deal with potential milestones over $170 million, and the launch of xPloration® Partner Access Program. Partner updates include positive clinical results for Immunovant's IMVT-1402 and batoclimab programs, and CStone's EMA submission for sugemalimab in NSCLC treatment.